Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 2
1921 1
1922 1
1923 1
1925 1
1928 1
1929 1
1936 1
1945 2
1949 1
1957 1
1961 1
1965 3
1968 1
1969 2
1972 4
1973 3
1975 3
1976 6
1977 3
1978 2
1979 3
1980 3
1981 1
1982 4
1983 1
1987 1
1988 2
1989 2
1990 3
1992 2
1993 1
1994 2
1995 5
1996 4
1997 3
1999 6
2000 1
2001 2
2002 2
2004 4
2005 1
2006 3
2007 5
2008 4
2009 5
2010 3
2011 11
2012 5
2013 5
2014 3
2015 1
2016 4
2017 4
2018 5
2019 5
2020 5
2021 5
2022 6
2023 4
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.
GBD 2019 Healthcare Access and Quality Collaborators. GBD 2019 Healthcare Access and Quality Collaborators. Lancet Glob Health. 2022 Dec;10(12):e1715-e1743. doi: 10.1016/S2214-109X(22)00429-6. Epub 2022 Oct 6. Lancet Glob Health. 2022. PMID: 36209761 Free PMC article.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Among authors: joffe j. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
Akinetopsia: A Systematic Review.
Van Swol JM, Thompson EB, Joffe JA, Nguyen SA, Berman EL. Van Swol JM, et al. Among authors: joffe ja. J Neuroophthalmol. 2024 Sep 1;44(3):e483-e488. doi: 10.1097/WNO.0000000000002032. Epub 2023 Nov 3. J Neuroophthalmol. 2024. PMID: 37938052 Review.
Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Oliver RT, et al. Among authors: joffe jk. J Clin Oncol. 2011 Mar 10;29(8):957-62. doi: 10.1200/JCO.2009.26.4655. Epub 2011 Jan 31. J Clin Oncol. 2011. PMID: 21282539 Clinical Trial.
Nitrate methemoglobinemia.
MARCUS H, JOFFE JR. MARCUS H, et al. Among authors: joffe jr. N Engl J Med. 1949 Apr 14;240(15):599-602. doi: 10.1056/NEJM194904142401503. N Engl J Med. 1949. PMID: 18115437 No abstract available.
Etoposide-related myocardial infarction.
Airey CL, Dodwell DJ, Joffe JK, Jones WG. Airey CL, et al. Among authors: joffe jk. Clin Oncol (R Coll Radiol). 1995;7(2):135. doi: 10.1016/s0936-6555(05)80819-2. Clin Oncol (R Coll Radiol). 1995. PMID: 7619765
Germ Cell Tumors in Adolescents and Young Adults.
Calaminus G, Joffe J. Calaminus G, et al. Among authors: joffe j. Prog Tumor Res. 2016;43:115-27. doi: 10.1159/000447081. Epub 2016 Sep 5. Prog Tumor Res. 2016. PMID: 27595361 Review.
169 results